<DOC>
	<DOC>NCT01378364</DOC>
	<brief_summary>The aim of the study is to investigate safety, tolerability and pharmacokinetics of single rising doses of AbGn-168H administered by intravenous infusion or subcutaneous injection to healthy male volunteers.</brief_summary>
	<brief_title>Phase I Study of AbGn-168H in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Inclusion criteria: 1. Healthy males according to following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR)) within normal range, 12lead electrocardiogram (ECG), clinical laboratory tests 2. Body Mass Index (BMI) between 18.5 and 29.9 kg/m2 3. Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation Exclusion criteria: 1. Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance 2. Any evidence of a clinically relevant concomitant disease in the opinion of the investigator 3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological and hormonal disorders 4. Chronic or relevant acute infections including hepatitis and tuberculosis, or a positive PPD skin test (5 mm or greater) at screening or within the previous 3 months 5. History of relevant allergy/hypersensitivity (including allergy to drug or its excipients) 6. Use of biologic agents within 12 weeks prior to treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>